Compare Danaher Corporation (DHR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Eli Lilly And Co — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 6.8× Danaher Corporation's market cap, and Danaher Corporation pays the higher dividend (0.74%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Eli Lilly And Co for 93 Days on average.
| DHR | LLY | |
|---|---|---|
Market Cap | $152.87B | $1.04T |
Volume | 5,228,698 | 3,064,878 |
Sector | Health | Health |
52-Week High | $242.05 | $1.28K |
52-Week Low | $161.91 | $799.57 |
Typical Hold Time | 69 Days | 93 Days |
Enterprise Value | $175.08B | $1.09T |
Dividend Yield | 0.74% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
